# A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants

> **NCT06397144** · PHASE1 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Biological Availability
- Healthy Participants

## Interventions

- **DRUG:** Paxlovid
- **DRUG:** Paxlovid
- **DRUG:** Nirmatrelvir/ritonavir
- **DRUG:** Nirmatrelvir/ritonavir

## Key facts

- **NCT ID:** NCT06397144
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-08-15
- **Primary completion:** 2025-12-09
- **Final completion:** 2025-12-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor business decision to terminate study. Decision not due to major safety concerns or requests from any regulatory authorities.
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06397144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06397144, "A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06397144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*